Sirio Pharma Past Earnings Performance
Past criteria checks 5/6
Sirio Pharma has been growing earnings at an average annual rate of 10%, while the Personal Products industry saw earnings growing at 7.9% annually. Revenues have been growing at an average rate of 19.1% per year. Sirio Pharma's return on equity is 11.4%, and it has net margins of 8.1%.
Key information
10.0%
Earnings growth rate
7.2%
EPS growth rate
| Personal Products Industry Growth | 7.8% |
| Revenue growth rate | 19.1% |
| Return on equity | 11.4% |
| Net Margin | 8.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sirio Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 4,128 | 336 | 725 | 134 |
| 30 Jun 24 | 4,028 | 334 | 698 | 131 |
| 31 Mar 24 | 3,831 | 315 | 658 | 119 |
| 31 Dec 23 | 3,582 | 281 | 627 | 110 |
| 30 Sep 23 | 3,222 | 221 | 564 | 95 |
| 30 Jun 23 | 2,941 | 204 | 517 | 88 |
| 31 Mar 23 | 2,788 | 227 | 485 | 84 |
| 01 Jan 23 | 2,507 | 212 | 432 | 81 |
| 30 Sep 22 | 2,409 | 208 | 408 | 85 |
| 30 Jun 22 | 2,315 | 196 | 398 | 82 |
| 31 Mar 22 | 2,283 | 189 | 377 | 84 |
| 31 Dec 21 | 2,369 | 232 | 386 | 83 |
| 30 Sep 21 | 2,361 | 272 | 350 | 74 |
| 30 Jun 21 | 2,316 | 279 | 335 | 74 |
| 31 Mar 21 | 2,216 | 265 | 336 | 71 |
| 31 Dec 20 | 2,067 | 257 | 310 | 65 |
| 30 Sep 20 | 1,865 | 209 | 327 | 68 |
| 30 Jun 20 | 1,710 | 178 | 312 | 66 |
| 31 Mar 20 | 1,554 | 156 | 285 | 62 |
| 31 Dec 19 | 1,580 | 143 | 279 | 66 |
| 30 Sep 19 | 1,625 | 186 | 254 | 66 |
| 31 Dec 18 | 1,595 | 203 | 238 | 62 |
| 31 Dec 17 | 1,330 | 104 | 225 | 46 |
| 31 Dec 16 | 786 | 704 | 151 | 41 |
Quality Earnings: 300791 has high quality earnings.
Growing Profit Margin: 300791's current net profit margins (8.1%) are higher than last year (6.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300791's earnings have grown by 10% per year over the past 5 years.
Accelerating Growth: 300791's earnings growth over the past year (51.7%) exceeds its 5-year average (10% per year).
Earnings vs Industry: 300791 earnings growth over the past year (51.7%) exceeded the Personal Products industry -6%.
Return on Equity
High ROE: 300791's Return on Equity (11.4%) is considered low.